Novacta strengthens leadership team
This article was originally published in Scrip
Executive Summary
Novacta Therapeutics, a privately held UK anti-infective biotechnology company, has appointed Dr David Pompliano non-executive director. He will also provide strategic direction to the company's R&D team and will serve as chairman of the scientific advisory board. Dr Pompliano was formerly vice-president and worldwide basic research head of antimicrobials at Merck & Co.